UT Southwestern Initiates Research on Weight Loss Mechanisms in Obese HFpEF Patients
Prospective Observational Study of 100 Patients
The University of Texas Southwestern Medical Center is tracking 100 patients with heart failure with preserved ejection fraction (HFpEF) who are prescribed weight-loss medications for obesity or diabetes under NCT06930495. The study began in December 2024 and is currently recruiting, with a target end date of June 2026. As a non-interventional observational study without randomization or drug administration, it is not classified under FDA clinical phases. The study compares changes before and after at least a 7% weight loss at 9ā12 months to elucidate the pathways by which fat accumulation causes exercise intolerance.
Focus on Pathophysiology Rather Than Drug Comparison
The enrolled medications are not specific products but second-line standard-of-care therapies for diabetes and obesity used in clinical practice. Representative drugs include semaglutide (Wegovy, Ozempic) from Novo Nordisk (NVO), which activates glucagon-like peptide-1 receptor (GLP-1R), and tirzepatide (Zepbound, Mounjaro) from Eli Lilly (LLY), which targets both glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1R. The research team is analyzing how fat inflammation, microvascular perfusion, skeletal muscle oxidative capacity, and exercise tolerance interrelate with weight loss, rather than comparing drug efficacy.
Established Clinical Competition Landscape
Standard drugs for HFpEF include empagliflozin (Jardiance) from Boehringer Ingelheim and Eli Lilly, and dapagliflozin (Farxiga) from AstraZeneca (AZN), both of which inhibit sodium-glucose cotransporter-2 (SGLT2). The FDA approved Jardiance for heart failure in February 24, 2022, and Farxiga in May 8, 2023. In obese HFpEF, semaglutideās Phase 3 STEP-HFpEF program and tirzepatideās Phase 3 SUMMIT trial have established direct clinical evidence. In SUMMIT, cardiovascular death or heart failure worsening occurred in 9.9% of tirzepatide and 15.3% of placebo, with a hazard ratio of 0.62.
Commercial Value Lies in Patient-Selection Biomarkers
Wegovy was approved as a chronic weight management drug on June 4, 2021, and the FDA added an indication for reducing major adverse cardiovascular events in obese or overweight adults on March 8, 2024, distinct from HFpEF treatment. The global GLP-1 receptor agonist market is projected to reach USD 66.4 billion in 2025, highlighting the economic value of mechanistic differentiation. If this study links intramuscular fat, inflammation, or microvascular function as response indicators, it could stratify treatment effects beyond weight loss magnitude. However, as a single-center observational study of 100 patients, its primary role is to inform subsequent randomized trials by developing biomarkers and patient selection criteria rather than expanding commercial labeling.
From an investor perspective, this study provides mechanistic data to support the differentiation of semaglutide and tirzepatide as the USD 66.4 billion GLP-1 market expands into obese HFpEF in 2025. For researchers, it offers the opportunity to validate the biological basis of Phase 3 STEP-HFpEF and SUMMIT results by linking skeletal muscle oxidative capacity and microvascular perfusion before and after at least 7% weight loss in 100 patients. For the industry, it presents opportunities to develop biomarkers for selecting responsive patients or combining FDA-approved HF therapies like Jardiance and Farxiga with metabolic treatments. While not a registrational trial likely to trigger short-term valuation changes, it is appropriate for a Watchlist due to its potential to refine tirzepatideās hazard ratio of 0.62 observed in SUMMIT and improve the design of subsequent interventional trials.
Source: ClinicalTrials.gov (api_ct)